Clinical trials: Newly Diagnosed
Newly Diagnosed Multiple Myeloma
A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma
This study aims to evaluate the safety and efficacy of Linperlisib combined with the VRD regimen in the treatment of newly diagnosed patients with multiple myeloma.
- Trial name
- NCT06799676
- Testing
- a combination treatment of Linperlisib and the VRD regimen
- Where
- 3 sites in China
- Volunteers
- 42 people
- Sponsor
- Fuling Zhou
Newly Diagnosed Type 1 Diabetes Mellitus
UCMSCs Combined With Standard Therapy for the Treatment of Newly Diagnosed Type 1 Diabetes
The aim is to investigate the safety and tolerability of intravenous infusion of allogeneic umbilical cord mesenchymal stem cells in pediatric patients diagnosed with newly onset type 1 diabetes
- Trial name
- NCT06407297
- Testing
- UCMSCs
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shanghai Changzheng Hospital
Newly Diagnosed Multiple Myeloma
Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
Multiple myeloma (MM) is a malignant disease of the BM characterized by clonal expansion of plasma cells. Current guidelines recommend that newly diagnosed transplant-eligible patients with multiple myeloma (NDMMTE) shall undergo…
- Trial name
- ELIAS (NCT05665140)
- Testing
- Isatuximab, Lenalidomide, Bortezomib
- Where
- 6 sites in Germany
- Volunteers
- 100 people
- Sponsor
- University Hopsital Schleswig Holstein Campus Lübeck
Newly Diagnosed Pediatric Pontine Glioma, Newly Diagnosed Pediatric High Grade Glioma
A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas
The overall objective of this pilot study is to collect immunological and safety data following administration of vaccinations with HLA-A2. This data will be used to decide whether a larger study of clinical efficacy is warranted.
- Conditions
- Newly Diagnosed Pediatric Pontine Glioma, Newly Diagnosed Pediatric High Grade Glioma, Recurrent Pediatric High Grade Glioma, Recurrent Pediatric Low Grade Glioma
- Trial name
- NCT01130077
- Testing
- HLA-A2 restricted glioma antigen peptides vaccine, Poly-ICLC
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- James Felker
Newly Diagnosed Multiple Myeloma
Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
This is an open-label, single-arm, prospective study conducted in real-world clinical practice. It aims to evaluate the efficacy and safety in Chinese patients with newly diagnosed multiple myeloma who switch to carfilzomib-based…
- Trial name
- NCT06682156
- Testing
- Carfilzomib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Newly Diagnosed Diffuse Large B-cell Lymphoma
A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma
A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with newly Diagnosed Diffuse Large B-cell Lymphoma
- Trial name
- NCT06683885
- Testing
- Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Mingzhi Zhang
Newly-diagnosed Cancers, Non-cancer Controls
The Sanderson Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
This protocol is a prospective, case-control multi-center diagnostic study to assess the sensitivity and specificity of blood-based screening tests for the early detection of multiple cancers.
- Trial name
- NCT05516927
- Testing
- Freenome Test
- Where
- 23 sites in United States
- Volunteers
- 788 people, healthy volunteers welcome
- Sponsor
- Freenome Holdings Inc.
Mantle Cell Lymphoma, Newly-diagnosed Mantle Cell Lymphoma
Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL
This phase 2 trial studies the efficacy and safety of zanubrutinib plus rituximab followed by R-DHAOx (rituximab, dexamethasone, cytarabine and oxaliplatin) regimen then maintenance with zanubrutinib for newly-diagnosed Mantle…
- Trial name
- NCT04624958
- Testing
- Zanubrutinib and Rituximab, R-DHAOx, Zanubrutinib Maintenance
- Where
- 3 sites in China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Multiple Myeloma, Newly Diagnosed
Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)
MYLENE is a prospective, multicenter, NIS to evaluate the patient and HCP satisfaction of sc and iv application of daratumumab in routine clinical practice in Germany.
- Conditions
- Multiple Myeloma, Newly Diagnosed, Transplant Ineligible, Patient Satisfaction
- Trial name
- MYLENE (NCT05284591)
- Testing
- Daratumumab
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- iOMEDICO AG
Follicular Lymphoma, Newly Diagnosed
Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
To evaluate the efficacy and side effects of Zanubrutinib combined with Obinutuzumab (ZO) in the treatment of newly diagnosed follicular lymphoma.
- Trial name
- NCT06553352
- Testing
- Zanubrutinib combined with Obinutuzumab
- Where
- China
- Volunteers
- 39 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Acute Lymphoblastic Leukemia, Adult, Ph+ ALL
Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL
This is a phase II interventional trial to evaluate the efficacy of ponatinib plus reduced-intensity chemotherapy in the first-line treatment of adult patients with Ph+ acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, Adult, Ph+ ALL, Newly Diagnosed
- Trial name
- Pona-CELL (NCT04554459)
- Testing
- Ponatinib 15 MG Oral Tablet
- Where
- 7 sites in Czechia
- Volunteers
- 4 people
- Sponsor
- Institute of Hematology and Blood Transfusion, Czech Republic
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
The ZGR regimen limited-course regimen was designed to combine three targeted agents, zanubrutinib, obinutuzumab (a third-generation CD20 monoclonal antibody), and lenalidomide, to deepen the depth of remission in patients with…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed
- Trial name
- ZGR in TN CLL (NCT06547944)
- Testing
- Zanubrutinib, Lenalidomide, Obinutuzumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma, Newly Diagnosed Patients
Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients
To compare the efficacy of the combination of lenalidomide with low-dose melphalan versus high-dose melphalan in newly diagnosed, symptomatic MM patients.
- Trial name
- MPRvsMEL200 (NCT00551928)
- Testing
- Melphalan, Lenalidomide, Prednisone
- Where
- Italy
- Volunteers
- 402 people
- Sponsor
- Fondazione EMN Italy Onlus
Obese Impaired Glucose Tolerance, Newly Diagnosed Obese Type 2 Diabetic Patients
Characterization and Mechanism Research of the Pre-disease State of Obese Type 2 Diabetes Mellitus
Establish a comprehensive evaluation system for the progression of obese impaired glucose tolerance (IGT) to type 2 diabetes mellitus (T2DM) through cross-sectional studies; Constructing and validating a T2DM risk prediction…
- Trial name
- NCT06495814
- Testing
- 1/bag of Jinlida granules, 3 times/day, taken with hot water.
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- Fengmei Lian
Newly-diagnosed Crohn's Disease
Development and Validation of a Nomogram for Predicting Surgery in Newly-diagnosed Crohn's Disease: a Retrospective Cohort Study
A majority of patients with Crohn's disease undergo surgery during the disease course. We aimed to develop an easily available nomogram to predict the risk of surgery at diagnosis.
- Trial name
- NCT06457035
- Testing
- immunosuppressant
- Volunteers
- 490 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Newly Diagnosed Glioblastoma Multiforme
Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme
The purpose of this study is to test the safety and effects of a combination of a study drug, Lapatinib, plus the administration of standard radiation therapy and an FDA approved drug Temozolomide (chemotherapy agent) in patients…
- Trial name
- NCT01591577
- Testing
- Lapatinib/Temozolomide/radiation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Newly Diagnosed Immune Thrombocytopenia in Children, First Line Treatment
Two Regimens of IVIG in the Treatment of Newly Diagnosed ITP in Children
To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia, and to reduce related adverse reactions and economic…
- Trial name
- NCT05520892
- Testing
- intravenous immunoglobulin
- Where
- China
- Volunteers
- 580 people
- Sponsor
- Fujian Medical University Union Hospital
Newly Diagnosed Glioblastoma
Pembrolizumab for Newly Diagnosed Glioblastoma
The study explores the addition of pembrolizumab to temozolomide-based radiotherapy in patients with newly diagnosed glioblastoma.
- Trial name
- PERGOLA (NCT03899857)
- Testing
- Pembrolizumab
- Where
- 3 sites in Switzerland
- Volunteers
- 56 people
- Sponsor
- University of Zurich
Newly Diagnosed Glioblastoma
A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)
A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients with Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)
- Trial name
- NCT04600817
- Testing
- TJ107
- Where
- 16 sites in China, Hong Kong
- Volunteers
- 160 people
- Sponsor
- TJ Biopharma Co., Ltd.
Lymphoblastic Leukemia, Acute, Adult, Ph Negative ALL
Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)
This is a phase II interventional trial to evaluate the efficacy of blinatumomab followed by high-dose chemotherapy in the first-line treatment for Ph-negative acute lymphoblastic leukemia (ALL) in adults.
- Conditions
- Lymphoblastic Leukemia, Acute, Adult, Ph Negative ALL, Newly Diagnosed
- Trial name
- Blina-CELL (NCT04554485)
- Testing
- Blinatumomab
- Where
- 5 sites in Czechia
- Volunteers
- 27 people
- Sponsor
- Institute of Hematology and Blood Transfusion, Czech Republic